In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

Page Options

  • Print This Page
  • Email This Document

Search Trial Results

Clinical Trial Results - Progress in Cancer Care

These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.

The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.

Anastrozole Reduces Recurrence in Early Breast Cancer: 10-Year Results of the ATAC Trial
(Updated: 12/30/2010) - Anastrozole (Arimidex®) is better than tamoxifen (Nolvadex®) at preventing a recurrence of breast cancer in postmenopausal women with early-stage hormone receptor-positive tumors, according to a report published in Lancet Oncology on November 17, 2010.

Cetuximab Plus Chemotherapy Extends Survival for Advanced Lung Cancer
(Posted: 12/29/2010) - Patients with advanced non-small-cell lung cancer (NSCLC) who received cetuximab (Erbitux) plus chemotherapy lived on average 5 weeks longer than patients who received chemotherapy alone, according to results of a randomized phase III trial.

Trial Suggests New Treatment Option for Hodgkin Lymphoma
(Posted: 12/27/2010) - Intermediate results from a phase II clinical trial presented at the 2010 American Society of Hematology annual meeting indicate that an investigational agent called brentuximab vedotin may be an effective alternative for some patients with Hodgkin lymphoma who have few viable treatment options.

Regular Sunscreen Use May Reduce Invasive Melanoma Risk
(Posted: 12/27/2010) - Regular sunscreen use may reduce the risk of developing melanoma, according to results of a randomized controlled trial that were reported December 6, 2010, in the Journal of Clinical Oncology.

Novel Drug Effectively Shrinks Tumors in Hodgkin Lymphoma
(Posted: 12/07/2010) - An investigational drug composed of a monoclonal antibody linked to a potent chemotherapy agent led to complete or substantial tumor shrinkage in nearly 40 percent of patients with Hodgkin lymphoma in a phase I clinical trial, researchers reported November 4, 2010, in the New England Journal of Medicine.

< Previous  8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28  Next >